Today's After-Hours MoversAevi Genomic Medicine, Inc. (NASDAQ: GNMX) 70.4% LOWER; announced that the ASCEND trial, a genomically-guided Phase 2 double-blind ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE